

PARTICULARS TO APPEAR ON THE OUTER PACKAGE {Carton, 10 ml}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Lozenord 5 mg/ml solution for injection

2. STATEMENT OF ACTIVE SUBSTANCES

Meloxicam 5 mg/ml

3. PACKAGE SIZE

10 mL

4. TARGET SPECIES

Dogs and cats

5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Dogs: Musculo-skeletal disorders: single subcutaneous injection.
Post-operative pain: single intravenous or subcutaneous injection.
Cats: Post-operative pain: single subcutaneous injection.

Read the package leaflet before use.

7. WITHDRAWAL PERIODS

8. EXPIRY DATE

Exp. {mm/yyyy}
Once broached use within 28 days.
Once broached use by:

9. SPECIAL STORAGE PRECAUTIONS

Keep the vial in the outer carton in order to protect from light.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

User warnings:

Pregnant women should not administer this product. See full user warnings for details.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Accord Healthcare B.V

14. MARKETING AUTHORISATION NUMBER

Vm 42153/5001

15. BATCH NUMBER

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING
UNITS {Vial, 10ml}**

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Lozenord 5mg/ml solution for injection

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

Each ml contains:

Active substance:

Meloxicam 5 mg

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp {mm/yyyy}

Once broached use within 28 days.

Once broached use by:.....

PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Lozenord 5 mg/ml solution for injection for dogs and cats

2. Composition

Each ml contains:
Meloxicam 5 mg

Qualitative composition of excipients and other constituents	Quantitative composition
Ethanol anhydrous	150 mg

Clear yellow solution.

3. Target species

Dogs and cats

4. Indications for use

Dogs:

Alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders. Reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery.

Cats:

Alleviation of mild to moderate post-operative pain and inflammation following surgical procedures in cats, e.g. orthopaedic and soft tissue surgery

5. Contraindications

Do not use in pregnant or lactating animals.

Do not use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Do not use in animals less than 6 weeks of age nor in cats of less than 2 kg.

6. Special warnings

Special precautions for safe used in the target species:

Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity. During anaesthesia, monitoring and fluid therapy should be considered as standard practice.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Accidental self-injection may give rise to pain. People with known hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) should avoid contact with the veterinary medicinal product.

In case of accidental self-injection, seek medical advice immediately and show this package leaflet or the label to the physician.

This product can cause eye irritation. In case of contact with the eyes, immediately rinse thoroughly with water.

In view of the risk of accidental self-injection and the known adverse class-effects of NSAIDs and other prostaglandin inhibitors on pregnancy and/or embryofetal development, the veterinary medicinal product should not be administered by pregnant women or women attempting to conceive.

Pregnancy and lactation:

See section "Contraindications".

Interaction with other medicinal products and other forms of interaction:

Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects.

Meloxicam must not be administered in conjunction with other NSAIDs or glucocorticosteroids. Concurrent administration of potential nephrotoxic drugs should be avoided. In animals at anaesthetic risk (e.g. aged animals) intravenous or subcutaneous fluid therapy during anaesthesia should be taken into consideration. When anaesthesia and NSAID are concomitantly administered, a risk for renal function cannot be excluded.

Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such veterinary medicinal products should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacological properties of the products used previously.

Overdose (symptoms, emergency procedures, antidotes):

In case of overdose symptomatic treatment should be initiated.

Major incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

7. Adverse events

Very rare (<1 animal / 10,000 animals treated, including isolated reports)	Gastrointestinal ulceration, Elevated liver enzymes Appetite loss, vomiting, diarrhoea, blood in faeces, lethargy and renal failure
--	---

These side effects are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.

Anaphylactoid reactions have been observed very rarely from post-marketing safety experience and should be treated symptomatically.

If adverse reactions occur, treatment should be discontinued, and the advice of a veterinarian should be sought.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system at:
Website: <https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine>
e-mail: adverse.events@vmd.gov.uk

8. Dosage for each species, routes and method of administration

Dosage for each species

Dogs: single administration of 0.2 mg meloxicam/kg body weight (i.e. 0.4 ml/10 kg).

Cats: single administration of 0.3 mg meloxicam/kg body weight (i.e. 0.06 ml/kg).

Method and routes of administration Dogs:

Musculo-skeletal disorders: single subcutaneous injection.

Meloxicam 1.5 mg/ml oral suspension for dogs or Meloxicam 1 mg and 2.5 mg chewable tablets for dogs may be used for continuation of treatment at a dosage of 0.1 mg meloxicam/kg body weight, 24 hours after administration of the injection.

Reduction of post-operative pain (over a period of 24 hours): single intravenous or subcutaneous injection before surgery, for example at the time of induction of anaesthesia.

Cats:

Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery: single subcutaneous injection before surgery, for example at the time of induction of anaesthesia.

The rubber stopper should not be punctured more than 24 times.

9. Advice on correct administration

Particular care should be taken with regard to the accuracy of dosing. Avoid introduction of contamination during use.

10. Withdrawal periods

Not applicable

11. Special storage precautions

Keep out of the sight and reach of children.

Keep the vial in the outer carton in order to protect from light.

Shelf life after first opening the container: 28 days.

Do not use this veterinary medicinal product after the expiry date which is stated on the carton and the bottle after Exp. The expiry date refers to the last day of that month.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements. These measures should help to protect the environment.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. MARKETING AUTHORISATION NUMBERS AND PACK SIZES

Vm 42153/5001

Pack sizes

Colourless Type I glass injection vial of 10 ml, closed with a grey fluorotech rubber stopper and sealed with aluminium cap and flip off plastic tamper evident top.

Cardboard box containing a single glass vial.

15. PID LINK (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

16. Contact details

Marketing authorisation holder and contact details to report suspected adverse reactions:

Accord Healthcare B.V
Winthontlaan 200, Utrecht,
3526 KV, Netherlands
Telephone number: +44 (0) 208 901 3383

Manufacturer responsible for batch release:

Laboratori Fundació DAU
Calle Lletra C De La Zona Franca 12-14,
Poligono Industrial De La Zona Franca De Barcelona,
Barcelona, 08040, Spain

17. Other information

POM-V
For animal treatment only.

Gavin Hall

Approved: 23 July 2025